A Multicenter Study for the Discovery and Validation of ALS Biomarkers
Study Purpose:
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research.
Disease:
Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALSStudy Type:
Observational StudyStudy Category:
Biomarkers/ImagingStudy Status:
Not enrollingPhase:
Not ApplicableStudy Chair(s)/Principal Investigator(s):
Merit Cudkowicz, MD, MSc (Massachusetts General Hospital)
James D. Berry, MD, MPH (Massachusetts General Hospital)
Robert Bowser, PhD (Barrow Neurological Institute)
Robert Brown, MD, D. Phil (UMASS)
Kevin Boylan, MD (Mayo Clinic Jacksonville)
Jonathan Glass, MD (Emory University)
David Lacomis, MD (University of Pittsburgh)
Clinicaltrials.gov ID (11 digit #):
NCT01495390Neals Affiliated?
YesCoordinating Center Contact Information
Mass General HospitalDaniela Grasso / .(JavaScript must be enabled to view this email address) / 617-726-0842
.(JavaScript must be enabled to view this email address) Neurological Clinical Research Institute (NCRI)
165 Cambridge Street, 6th Floor
Boston, Massachusetts 02114 United States
Full Study Summary:
The purpose of the research study is to collect blood samples and cerebrospinal fluid (CSF) from people with amyotrophic lateral sclerosis (ALS). These samples will be collected approximately every 4 months. Through comparison of these specimens, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
Study Sponsor:
ALS Therapy AllianceParticipant Duration:
up to 36 months